ClinicalTrials.gg

Program

Losartan

Also written as “losartan potassium”, “Amlodipine plus Losartan” and “Losartan (COZZAR®)”.

Its studies are mostly in Hypertension · Essential Hypertension · Diabetes Mellitus, Type 2 · Proteinuria · Heart Failure, led by 11 companies.

Furthest: phase 4, since Aug 30, 200541 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organon120 open or runningphase 4since Aug 30, 2005Aug 25, 2004none ahead
Hanmi Pharmaceutical80 open or runningphase 3since Jul 14, 2009Jul 14, 2009none ahead
Merck60 open or runningphase 3since Apr 14, 2009Feb 27, 2009none ahead
Torrent Pharmaceuticals40 open or runningphase 1since Oct 7, 2010Oct 7, 2010none ahead
Hikma Pharmaceuticals30 open or runningno phasesince Apr 9, 2010Apr 9, 2010none ahead
Laboratorios Silanes S.A. de C.V.20 open or runningphase 3since Jun 8, 2021Jun 8, 2021none ahead
Teva Pharmaceutical Industries20 open or runningphase 1since May 13, 2010May 13, 2010none ahead
Azidus Brasil10 open or runningphase 1since Sep 21, 2012Sep 21, 2012none ahead
invasc-therapeutics-inc10 open or runningphase 4since Jan 5, 2011Jan 5, 2011none ahead
Medtronic10 open or runningearly phase 1since Jul 21, 2008Jul 21, 2008none ahead
Pharmtechnology10 open or runningphase 1since Feb 27, 2018Feb 27, 2018none ahead

Also a collaborator on its studies: reliance-life-sciences-private-limited.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 21 studies since Aug 25, 2004.

  1. May 13, 2010Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT01124175, NCT01124162
  2. May 19, 2010Phase 3 study in HypertensionHanmi Pharmaceutical · NCT01127217 · 149 enrolled · Korea, Republic of
  3. Sep 7, 20102 phase 1 studies in HealthyHanmi Pharmaceutical · NCT01197014, NCT01197001
  4. Oct 6, 20102 no phase studies in HypertensionHikma Pharmaceuticals · NCT01216878, NCT01216852
  5. Oct 7, 2010Torrent Pharmaceuticals's first studies: 4 phase 1 studies in HealthyNew to Torrent PharmaceuticalsTorrent Pharmaceuticals · NCT01218724, NCT01218711, NCT01218698 and 1 more
  6. Jan 5, 2011invasc-therapeutics-inc's first study: phase 4 study in HypertensionNew to invasc-therapeutics-incinvasc-therapeutics-inc · NCT01271374 · 80 enrolled · United States
  7. Feb 22, 2011Phase 3 study in HypertensionMerck · NCT01302691 · 327 enrolled
  8. Sep 7, 2011Phase 4 study in HypertensionOrganon · NCT01431508 · 15 enrolled
  9. Sep 21, 2012Azidus Brasil's first study: phase 1 study in Healthy SubjectsNew to Azidus BrasilAzidus Brasil · NCT01692717 · 90 enrolled · Brazil
  10. Dec 17, 2014Phase 1 study in HypertensionHanmi Pharmaceutical · NCT02387554 · 33 enrolled · Korea, Republic of
  11. Feb 23, 2016Phase 1 study in HealthyHanmi Pharmaceutical · NCT04252872 · 64 enrolled · Korea, Republic of
  12. Feb 27, 2018Pharmtechnology's first study: phase 1 study in HealthyNew to PharmtechnologyPharmtechnology · NCT03459911 · 66 enrolled · India
  13. Jun 8, 2021Laboratorios Silanes S.A. de C.V.'s first study: phase 3 study in HypertensionNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT04927299 · 163 enrolled · Mexico
  14. Oct 8, 2021Phase 1 study in HealthyLaboratorios Silanes S.A. de C.V. · NCT05090449 · 36 enrolled · Mexico

TargetBeta

AGTR1 →read by rule
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule

Other programs on AGTR1

ProgramCompanyFurthest phaseStudies
ValsartanruleNovartisphase 4145
TelmisartanruleBoehringer Ingelheimphase 4132
azilsartan medoxomilruleTakedaphase 425
sparsentanruletravere-therapeutics-incphase 49

Studies

All 41 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05090449Healthy · Mexico1CompletedLaboratorios Silanes S.A. de C.V.Apr 8, 202036
NCT04927299Hypertension · Mexico3CompletedLaboratorios Silanes S.A. de C.V.Aug 15, 2023163
NCT03459911Healthy · India1CompletedPharmtechnologyMar 11, 201866
NCT04252872Healthy · Korea, Republic of1CompletedHanmi PharmaceuticalNov 201564
NCT02387554Hypertension · Korea, Republic of1CompletedHanmi PharmaceuticalOct 201433
NCT01692717Healthy Subjects · Brazil1CompletedAzidus BrasilMay 31, 201390
NCT01431508Hypertension4CompletedOrganonJun 1, 200915
NCT01302691Hypertension3CompletedMerckApr 1, 2012327
NCT01271374Hypertension · United States4UNKNOWNinvasc-therapeutics-incJun 201180
NCT01218724Healthy · India1CompletedTorrent Pharmaceuticals
NCT01218711Healthy1CompletedTorrent Pharmaceuticals
NCT01218698Healthy · India1CompletedTorrent Pharmaceuticals
NCT01218022Healthy · India1CompletedTorrent Pharmaceuticals
NCT01216878Hypertension · United States–CompletedHikma PharmaceuticalsSep 200440
NCT01216852Hypertension · United States–CompletedHikma PharmaceuticalsAug 200440
NCT01197014Healthy · Czech Republic1CompletedHanmi PharmaceuticalNov 201072
NCT01197001Healthy · Czech Republic1CompletedHanmi PharmaceuticalOct 201072
NCT01127217Hypertension · Korea, Republic of3CompletedHanmi PharmaceuticalMar 2010149
NCT01124175Healthy · Canada1CompletedTeva Pharmaceutical IndustriesNov 200380
NCT01124162Healthy · Canada1CompletedTeva Pharmaceutical IndustriesNov 200380
NCT01102478Hypertension · United States–CompletedHikma PharmaceuticalsMar 200530
NCT00953680Hypertension1CompletedOrganonMay 200477
NCT00943852Hypertension1CompletedOrganonDec 200613
NCT00942344Hypertension · Korea, Republic of2CompletedHanmi PharmaceuticalDec 2007320
NCT00940680Hypertension · Korea, Republic of3CompletedHanmi PharmaceuticalNov 2008142
NCT00940667Hypertension · Korea, Republic of3CompletedHanmi PharmaceuticalDec 2008185
NCT00888355Hypertension3CompletedMerckJan 1993428
NCT00887250Hypertension3CompletedMerckAug 1992366
NCT00886600Hypertension3CompletedMerckMay 1992122
NCT00882440Hypertension3CompletedMerckAug 1991576
NCT00856960Hypertension1CompletedMerckMar 201012
NCT00756938Hypertension3CompletedOrganonAug 14, 2012101
NCT00720577Peripheral Arterial DiseaseEarly 1CompletedMedtronicJul 2007164
NCT00568178Proteinuria3CompletedOrganonSep 1, 2008306
NCT00496834Hypertension4CompletedOrganonSep 1, 2009201
NCT00449111Hypertension3TerminatedOrganonSep 30, 200611
NCT00308347Diabetes Mellitus, Type 23CompletedOrganonFeb 20011,513
NCT00307060Mild to Severe Hypertension3CompletedOrganonJun 1, 2005274
NCT00289887Hypertension3CompletedOrganonFeb 2007261
NCT00140907Hypertension4CompletedOrganonJan 1, 2005367
NCT00090259Heart Failure3CompletedOrganonMar 31, 20093,834

How it is read

Names in the registry

  • “losartan potassium”, 10 entries
  • “Losartan”, 8 entries
  • “Amlodipine plus Losartan”, 5 entries
  • “Losartan (COZZAR®)”, 2 entries
  • “Experimental: Sacubitril/Allisartan and Amlodipine Group”, 2 entries

Codes read as this program: MK0954.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.